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ABSTRACT
The objective of this randomized clinical trial was 
to compare the effect of revaccination in primiparous 
dairy cows with modified live viral (MLV) or killed 
viral (KV) vaccines containing bovine viral diarrhea vi-
rus (BVDV) and bovine herpesvirus-1 (BoHV-1) on (1) 
pregnancy rate following estrus synchronization-timed 
artificial insemination (TAI), (2) serum progesterone 
concentrations, and (3) serum neutralizing antibody 
titers at revaccination and at TAI. Primiparous dairy 
cows (n = 692) that had been previously vaccinated 
with 4 doses of MLV vaccine as calves or heifers were 
randomized to receive either an MLV or a KV vaccine 
between 21 and 28 d in milk and 17 d before initiation 
of a double-Ovsynch-TAI protocol. Serum was collected 
within the double-Ovsynch protocol for determination 
of progesterone concentrations, and at vaccination and 
TAI for serum neutralizing antibody titers. Ultrasound 
pregnancy determinations were made at 30 and 60 d 
after TAI. No differences in pregnancy rates were ob-
served between cows receiving MLV vaccine (44%; n = 
326) or KV vaccine (43%; n = 336). No differences were 
observed in serum progesterone concentrations during 
a double-Ovsynch-TAI protocol between cows receiving 
MLV and KV vaccines. No differences were observed 
in BVDV 1 or BVDV 2 antibody titers at vaccination 
and TAI between cows receiving MLV or KV vaccine; 
however, BoHV-1 antibody titers were greater at TAI 
in cows receiving KV vaccine. Overall response to vac-
cination—defined as the percent of all individual cows 
that had any detectable increase in antibody titer from 
vaccination to TAI—was 39% for BVDV 1, 45% for 
BVDV 2, and 61% for BoHV-1. In this research, use of 
an MLV vaccine did not impede reproduction when re-
vaccination was performed between 21 and 28 DIM and 
just before enrollment in an estrus synchronization-TAI 
program in primiparous dairy cows; however, response 
to vaccination as defined by increases in virus-specific 
antibody titers could be considered less than ideal for 
this population of cattle.
Key words: immunity, vaccination, modified-live 
viral, killed viral
INTRODUCTION
Dairy herd profitability is predicated on reproductive 
performance because pregnancy and parturition initi-
ate and renew lactation cycles. Reproductive efficiency 
of dairy herds is greatly affected by pregnancy losses 
due to infectious disease. Bovine viral diarrhea virus 
(BVDV) and bovine herpesvirus-1 (BoHV-1) are 
important viral pathogens of the bovine reproductive 
tract, resulting in infertility, abortions, and birth of 
calves with poor health (Walz et al., 2010; Givens et al., 
2012). These pathogens and their respective diseases 
are present in dairy herds worldwide, thus affecting re-
productive and overall efficiency of the dairy industry. 
Vaccination provides an important contribution to lim-
iting reproductive losses associated with these viral in-
fections and is an important control procedure to limit 
transmission of BVDV and BoHV-1 among dairy cattle 
populations. Modified-live viral (MLV) or killed viral 
(KV) vaccines are available for BVDV and BoHV-1, 
often in multivalent formulations. Although MLV vac-
cines containing BVDV and BoHV-1 are considered to 
provide longer immunity and greater protection against 
reproductive loss (Rodning et al., 2010; Givens et al., 
2012), concerns have been expressed regarding the safe-
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ty of these multivalent vaccines on female reproduction, 
with the majority of concern focused on the BoHV-1 
fractions of the MLV vaccines causing abortions when 
given to pregnant cattle (O’Toole et al., 2012, 2014). 
An additional safety concern associated with MLV vac-
cines containing BVDV and BoHV-1 is infertility when 
MLV vaccines are administered in proximity to time 
of breeding (Van der Maaten and Miller, 1985; Chiang 
et al., 1990; Smith et al., 1990; Perry et al., 2013). 
Use of MLV vaccines in naïve heifers at the onset of 
standing estrus has been demonstrated to have nega-
tive effects on function of the corpus luteum (Van der 
Maaten and Miller, 1985; Smith et al., 1990). Further-
more, timing of a BoHV-1 viremia within the stage of 
the estrous cycle is a critical determinant of negative 
effects on estrous cyclicity and fertility. When BoHV-1 
viremia occurs as a result of MLV vaccination during 
development of the corpus luteum after ovulation, se-
vere necrotizing lesions develop (Van der Maaten et 
al., 1985; Miller and Van der Maaten, 1986). Severe 
necrotizing lesions within the corpus luteum have been 
associated with decreased circulating concentrations of 
progesterone (P4), prolonged interestrus intervals, and 
a subsequent, transient subfertility.
Efficient reproduction is important for optimal prof-
itability on dairy cattle farms (Wiltbank et al., 2011). 
Many dairy farms do not attain optimal reproduction 
because of numerous factors related to management, 
health, and physiology of the lactating dairy cow. To 
circumvent some of the management problems, estrus 
synchronization programs have become standard com-
ponents in the current breeding management of cows 
on most dairy operations (Macmillan, 2010). Many 
synchronization programs are based on protocols that 
allow timed inseminations (TAI) to bypass practical 
difficulties associated with estrus detection. Almost 
all programs involve strategically timed injections of 
PGF2α and GnRH. While dairies are managing repro-
duction, attention must also be given to immunization 
against reproductive pathogens including BVDV and 
BoHV-1. Many large dairy operations utilize MLV 
vaccination against reproductive pathogens during the 
early postpartum period, and these vaccine admin-
istrations often occur within 2 to 4 wk of initiating 
estrus synchronization and TAI protocols. Because of 
the concerns associated with MLV vaccine usage on 
dairy cow reproductive performance, the overall goal 
of this study was to examine MLV vaccination in pri-
miparous dairy cows where vaccination and initiation 
of an estrus synchronization-TAI program occurred 
in close time proximity. The null hypothesis was that 
MLV revaccination within 28 d of the initiation of a 
double-Ovsynch protocol would not result in transient 
subfertility and affect response to synchronization and 
pregnancy rate at TAI. Thus, the objective of this re-
search was to compare the effect of revaccination in 
postpartum primiparous dairy cows at 21 to 28 d after 
calving with MLV or KV vaccination on (1) pregnancy 
rate, (2) serum P4 concentrations at 3 critical times 
during a double-Ovsynch/TAI protocol, and (3) serum 
neutralizing antibody titers at vaccination and at TAI.
MATERIALS AND METHODS
Animals
Six hundred ninety-two primiparous cows were used 
for the current study. The study was conducted on 
a large commercial dairy farm (3,300 lactating dairy 
cows) located in Saranac, Michigan, between August 
2013 and February 2014. All primiparous cows were 
housed in freestall barns separate from multiparous 
cows, milked 3 times daily, provided ad libitum access 
to water, and fed twice daily a TMR that was bal-
anced to meet or exceed nutrient recommendations for 
primiparous lactating dairy cows. All study procedures 
were approved by the Auburn University Animal Care 
and Use Committee (PRN 2013–2274) and the Auburn 
University Clinical Research Review Committee. All 
primiparous cows enrolled in this study had received 3 
MLV (Express FP 10, Boehringer Ingelheim Vetmedica 
Inc., St. Joseph, MO) vaccinations as young calves at 
the farm of origin (at 5 wk of age, at 3–4 mo of age, and 
at 6–7 mo of age), and 1 MLV (Express FP 10, Boeh-
ringer Ingelheim Vetmedica Inc.) vaccination while at 
a commercial heifer breeding facility in Garden City, 
Kansas, at approximately 2 mo before calving. Prepar-
tum heifers were transported from the heifer breeding 
facility to the dairy at approximately 2 mo before the 
calving date. Following calving, only primiparous cows 
were enrolled that did not possess any of the follow-
ing exclusion criteria: (a) BCS of 1 or 5, (b) history 
of retained fetal membranes, (c) treatment for uterine 
infections within the first 14 DIM, or (d) surgical cor-
rection of a displaced abomasum within first 14 DIM. 
Lists of eligible cows between 14 and 21 DIM were sent 
electronically every week to Auburn University for 
randomization to study group and for blood sampling. 
Enrollment dates for study cows occurred from June 
24, 2013, to January 28, 2014. Eligible cows were ran-
domly assigned to group A or group B using random 
number generator function of commercially available 
software (Excel, Microsoft Corp., Redmond, WA). Ran-
dom numbers were generated for each cow and sorted 
from low to high. For each enrollment date, the low-
est half of random numbers were assigned to group A 
and the highest half of random numbers were assigned 
to group B. Once cows were assigned to a treatment 
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group, the random number generator function was 
again used to generate the subset of cows within each 
group for blood sampling at vaccination and during the 
estrus synchronization-TAI program. Equal numbers of 
cows within each group at each enrollment date were 
randomly assigned for blood sampling.
Study Design and Sampling
This was a randomized clinical trial (Figure 1). Be-
tween 21 and 28 DIM, all cows were vaccinated accord-
ing to group assignment. At the time of vaccination, 
which corresponded to study d 0, a blood sample was 
collected from the subset of cows randomly selected for 
blood sampling within each group. This initial blood 
sample was tested for neutralizing antibody concentra-
tions to BVDV 1, BVDV 2, and BoHV-1. As part of 
farm protocol, all primiparous cows were subjected 
to an estrus synchronization-TAI protocol (Souza et 
al., 2008), with TAI occurring by 70 DIM. On d 17 
(at approximately 40 DIM), all cows began the estrus 
synchronization-TAI program by receiving 100 μg of 
GnRH (Fertagyl; Merck Animal Health, Millsboro, 
DE). On study d 24, blood was again collected on the 
subset of cows randomly selected for blood sampling 
within each group, and this blood sample coincided 
with the first PGF2α (500 μg of cloprostanol sodium, 
Estrumate; Merck Animal Health) administration as 
part of the pre-Ovsynch. On study d 42, another blood 
sample was collected from the subset of cows randomly 
selected for blood sampling. This sample was also pro-
cessed for analysis of serum P4 concentrations, and this 
period coincided with the second PGF2α administration 
as part of the breeding-Ovsynch. Finally, a fourth blood 
sample was collected at TAI, which occurred on study d 
45. This blood sample was processed and tested for P4 
concentrations and for serum neutralizing antibody ti-
ters to BVDV 1, BVDV 2, and BoHV-1. All cows were 
checked for pregnancy by ultrasound at approximately 
30 d after TAI and again at 60 d after TAI. All cow 
records, including health records and pregnancy testing 
results were recorded using electronic record-keeping 
software (DairyComp 305, Valley Agricultural Software 
Inc., Tulare, CA).
Vaccination
Primiparous cows randomly assigned to group A 
were vaccinated with a commercially available MLV 
combination vaccine (Express FP 10, Boehringer In-
gelheim Vetmedica Inc.). Cows randomly assigned to 
group B were vaccinated with a commercially available 
KV combination vaccine (Triangle 10, Boehringer In-
gelheim Vetmedica Inc.). Vaccines were administered 
subcutaneously according to label directions. The 
commercially available MLV combination vaccine 
(Express FP 10) and the commercially available KV 
combination vaccine (Triangle 10) contained the fol-
lowing viral fractions: BoHV-1, BVDV type 1, BVDV 
type 2, bovine parainfluenza-3, and bovine respira-
tory syncytial virus, and the following bacterial frac-
tions: Leptospira canicola, Leptospira grippotyphosa, 
Leptospira hardjo, Leptospira pomona, and Leptospira 
icterohemorrhagiae.
Figure 1. Study design and sample collection strategy. All primiparous cows were randomly assigned to group A or B and vaccinated accord-
ing to group designation between 21 and 28 DIM. Group A cows received a multivalent modified-live viral vaccine (Express FP 10, Boehringer 
Ingelheim Vetmedica Inc., St. Joseph, MO), whereas group B cows received a multivalent killed viral vaccine (Triangle 10, Boehringer Ingelheim 
Vetmedica Inc.). Blood was collected from a randomly selected subset of cows from each group for determination of progesterone concentrations 
and antibody titers by serum virus neutralization. Sampling arrows are approximate DIM. TAI = timed AI; VN = virus neutralization assay; 
P4 = progesterone.
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Serum P4
Blood was collected from the randomly selected sub-
set of cows and processed within 1 h of collection. Blood 
was centrifuged (1,200 × g for 30 min) to obtain serum. 
Serum samples were frozen and subsequently analyzed 
for concentrations of P4. Progesterone concentrations 
were measured using an RIA kit (Coat-a-Count, Sie-
mens Healthcare Diagnostics Inc., Los Angeles, CA) 
previously validated for bovine serum (Stevenson et 
al., 2012). Intra- and interassay coefficients of variation 
were both <10%. The sensitivity of this assay was 0.1 
ng/mL.
Virus Neutralization Assays
The standard virus neutralization (VN) microtiter 
assay was used to detect serum antibodies directed 
against BVDV-1, BVDV-2, and BoHV-1 (Walz et al., 
2008; Givens et al., 2012). Serum was collected for VN 
assays at vaccination and at TAI. The BVDV-1 cy-
topathic strain NADL, the BVDV-2 cytopathic strain 
125c, and the BoHV-1 Colorado strain were used as 
test viruses. Briefly, after heat inactivation at 56°C for 
30 min, serial 2-fold dilutions (1:2 to 1:4,096) of serum 
were made in 50 μL of culture medium. For each dilu-
tion, 3 wells of a 96-well polystyrene microtiter plate 
(Falcon tissue culture plates; Corning Life Sciences DL, 
Corning, NY) were inoculated with an equal volume 
(50 μL) of culture medium containing a median tissue 
culture infective dose (TCID50) of the test strain of 100 
to 500/mL. After inoculation, the plate was incubated 
at 37°C in a humidified atmosphere of 5% CO2 and air 
for 1 h. Then, 2.5 × 103 Madin-Darby bovine kidney 
(MDBK) cells in 50 μL of culture medium were added 
to each well. The plate was incubated for 72 h and 
evaluated visually for a cytopathic effect. Mean log2 
antibody titers were calculated from the endpoint titers 
for the animals in each group.
Statistical Analyses
All statistical analyses were performed using com-
mercially available statistical software (JMP and SAS 
9.3, SAS Institute Inc., Cary, NC). Categorical data 
including outcome of AI (pregnant, open, or aborted) 
and response to vaccination (seroconversion or no re-
sponse) were compared between groups using Fisher’s 
Exact test. In addition, the pregnancy rate was com-
pared with the response to vaccination within groups 
for primiparous cows that were randomly selected for 
blood sampling using Fisher’s Exact test. Continuous 
data were evaluated for normality by visual inspection 
of histograms and normal quantile plots as well as by 
formal testing for departures from normality using the 
Shapiro-Wilk W-test. Variables that violated the as-
sumption of normality included DIM at vaccination, 
DIM at start of pre-Ovsynch, DIM at TAI, and days 
between vaccination and TAI, which were analyzed us-
ing the nonparametric Wilcoxon test.
The response variables P4 concentration and an-
tibody titers were measured repeatedly on the same 
experimental unit; therefore, data were analyzed us-
ing repeated-measures methodology using the follow-
ing model: response = group + time + group × time. 
Post hoc pairwise comparisons were performed using 
Tukey’s honestly significant difference (HSD) test. Se-
rum antibody titers against each virus evaluated were 
subjected to a logarithmic transformation to normalize 
the distribution of the data, which were subsequently 
analyzed by the use of multivariate repeated-measures 
ANOVA. For analysis, the reciprocal of serum anti-
body titers was log2-transformed, which were then 
back-transformed as geometric means for presentation 
of results. If differences between groups were detected 
over time, the geometric means of the reciprocal of the 
antibody titers were compared at each time point using 
an ANOVA F-test. Progesterone concentrations at vari-
ous time points were compared using multivariate re-
peated-measures ANOVA. If differences among groups 
were detected over time, the results were compared at 
each time point using an ANOVA F-test.
RESULTS
A total of 692 cows were randomized into 2 equal 
group sizes for enrollment in this study, with 346 cows 
enrolled in group A (Express FP 10) and 346 enrolled 
in group B (Triangle 10). Four group A cows and 2 
group B cows were disqualified from study between 
the time of randomization and the date of vaccination 
because of health issues, resulting in group sizes of 342 
group A cows and 344 group B cows (total of 686 cows 
that were vaccinated; Table 1). Descriptive statistics 
were performed on group characteristics (Table 2), and 
no differences were observed between groups A and B 
for DIM at vaccination (P = 0.46), DIM at start of 
pre-Ovsynch (P = 0.28), DIM at TAI (P = 0.37), and 
number of days between vaccination and TAI (P = 
0.28). With respect to DIM at the time of vaccination, 
all 342 group A cows received MLV vaccine between 21 
and 27 DIM, whereas 340 group B cows received KV 
vaccine between 21 and 27 DIM, and the remaining 4 
cows received KV vaccine at 28 DIM; thus, all cows 
enrolled in this study were vaccinated between 21 and 
28 DIM. The average days between vaccination and the 
first GnRH administration as part of the pre-Ovsynch 
protocol was 17.38 d (range: 6–60 d) and 17.58 d (range: 
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8–48 d) for groups A and B, respectively. In group A, 
286 of the 342 cows vaccinated (84%) were given their 
vaccine exactly 17 d before the first GnRH administra-
tion as part of the pre-Ovsynch protocol. In group B, 
296 of the 344 cows (86%) were given their vaccine 
exactly 17 d before the first GnRH administration as 
part of the pre-Ovsynch protocol.
Of the 342 group A cows administered MLV vac-
cine, insemination at TAI was performed in 326 cows 
(95%). Of the 344 group B cows administered KV 
vaccine, insemination at TAI was performed in 336 
cows (98%). Reasons for cows to be enrolled but not 
inseminated (total n = 24; Table 1) included sold-lame 
(n = 6), sold-poor production (n = 2), sold-leg injury 
(n = 1), sold-pneumonia (n = 2), sold-mastitis (n = 
1), sold-undetermined (n = 1), sold-listeria (n = 1), 
died-pneumonia (n = 1), do not breed (DNB)-kicker 
(n = 2), DNB-poor production (n = 2), DNB-uterine 
adhesions (n = 1), bred late (n = 2), pyometra (n = 1), 
and hospital mastitis (n = 1).
Of the 686 study cows that received vaccine, 226 
cows (n = 111 for group A; n = 115 for group B) were 
selected for blood sampling. Complete blood samples 
(vaccination, 1st PGF2α, 2nd PGF2α, and TAI) were 
available for 88 group A cows (79%) and 91 group B 
cows (79%).
Pregnancy Rate
Overall pregnancy rate was 43% for enrolled cows, 
with pregnancy rates of 44% and 43% for group A and 
group B cows, respectively (Table 2). This pregnancy 
rate is defined as the cows detected pregnant at the 
30-d ultrasound pregnancy check and confirmed preg-
nant at the 60-d ultrasound pregnancy check. For the 
cows that were inseminated, 9 group A cows and 19 
group B cows were determined to be pregnant at the 
30-d ultrasound pregnancy check but then diagnosed 
as open at the 60-d pregnancy check. The causes of 
fetal loss after d 30 and before d 60 of gestation were 
undetermined. No significant differences in pregnancy 
rate and abortion rate were detected between group A 
and group B cows (Table 2).
Serum P4
Serum P4 concentrations were evaluated on the sub-
set of cows randomly selected for bleeding. Complete 
sets of samples for P4 analysis (1st PGF2α, 2nd PGF2α, 
and TAI) were available for 88 group A cows (79%) and 
91 group B cows (79%). Individual samples from group 
A and group B cows were available for testing, with a 
final sample size of 95, 104, and 103 for group A cows 
Table 1. Outcomes for project cows according to group allocation1
Group
No. of cows randomly  
selected for study
No. of cows  
initially excluded2
No. of  
DNB cows3
No. of open  
cows4
No. of  
pregnant cows5
No. of cows  
that aborted6
Group A 346 4 16 175 142 9
Group B 346 2 8 173 144 19
1Group A cows received a multivalent modified-live viral vaccine (Express FP 10, Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO), 
whereas group B cows received a multivalent killed viral vaccine (Triangle 10, Boehringer Ingelheim Vetmedica Inc.). Of the 692 cows selected 
for study, 326 group A and 336 group B cows were inseminated. Breeding results at timed AI were determined by ultrasound pregnancy check 
at 30 and 60 d after insemination.
2Cows that were excluded after randomization but before vaccination.
3Cows vaccinated but not inseminated (DNB = did not breed; e.g., sold, died, uterine adhesions, temperament).
4Cows not pregnant at 30-d ultrasound pregnancy check.
5Cows confirmed pregnant at 30-d and 60-d ultrasound pregnancy check.
6Cows confirmed pregnant at 30-d but were not pregnant at 60-d ultrasound pregnancy check.
Table 2. Descriptive statistics for average DIM at vaccination, average DIM at timed AI (TAI), average days between vaccination and TAI, and 
statistical comparisons between groups1 on primary outcome measurements of pregnancy rate and abort rate
Group
DIM at vaccination 
(mean ± SEM)








Group A 24.02 ± 0.11 68.41 ± 0.23 44.38 ± 0.24 43.6 2.8
Group B 23.89 ± 0.10 68.47 ± 0.19 44.58 ± 0.18 42.9 5.7
P-value 0.46 0.37 0.28 0.94 0.11
1Group A cows received a multivalent modified-live viral vaccine (Express FP 10, Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO), 
whereas group B cows received a multivalent killed viral vaccine (Triangle 10, Boehringer Ingelheim Vetmedica Inc.). 
2Pregnancy rate is defined as percent of eligible cows that became pregnant.
3Abortion rate is defined as percent of cows confirmed pregnant at 30-d ultrasound pregnancy check that were found not pregnant at 60-d ul-
trasound pregnancy check.
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at 1st PGF2α, 2nd PGF2α, and TAI, respectively, and a 
final sample size of 99, 102, and 103 for Group B cows 
at 1st PGF2α, 2nd PGF2α, and TAI, respectively. The 
mean serum P4 concentrations were lower at 1st PGF2α 
than at 2nd PGF2α. The mean serum P4 concentration 
was lowest at TAI. No significant differences were noted 
in serum P4 concentrations at any time point between 
groups (Figure 2).
BVDV- and BoHV-1-Specific Antibody 
Determinations by Virus Neutralization
Antibody titers were determined at vaccination and 
at TAI for 104 group A cows and 104 group B cows. 
At the time of vaccination, all cows possessed neutral-
izing antibody titers to BVDV 1 and BVDV 2, except 
1 group B cow that was seronegative to BVDV 1 and 
BVDV 2 at vaccination. With respect to the magnitude 
of BVDV antibody titers at the time of vaccination, all 
cows had BVDV 1 and BVDV 2 titers >16, except for 
4 group A cows and 6 group B cows that had antibody 
titers to BVDV 2 of <16. In addition, all cows except 
for 8 group A cows and 9 group B cows had BVDV 1 
antibody titers ≤1,024. For the BoHV-1 antibody titers, 
all project cows had neutralizing titers except 5 group 
A cows and 6 group B cows, which were seronegative to 
BoHV-1 at the time of vaccination.
The geometric mean antibody titer increased in 
group A and group B cows between vaccination and 
TAI, which was approximately 45 d after vaccination 
(Table 3). No significant differences in antibody titers 
were detected between group A and group B cows with 
respect to BVDV 1 and BVDV 2 neutralizing antibody 
titers at vaccination or at TAI; however, a significantly 
higher BoHV-1 antibody titer was present at TAI in 
group B cows compared with group A cows.
The neutralizing antibody titers between samples 
taken at vaccination and samples taken at TAI were 
also evaluated for each individual cow to determine an 
individual cow’s response to vaccination (Figure 3). To 
determine the response to vaccination, we calculated 
the difference between the log2 titer at vaccination and 
at TAI. For example, a titer of 16 (log2 = 4) at vac-
cination and a titer of 64 (log2 = 6) at TAI would 
have a calculated difference of 2. Furthermore, a posi-
tive response to vaccination was defined as a difference 
between the log2 titer at vaccination and TAI ≥1. A 
nonresponse to vaccination was defined as a difference 
between the log2 titer at vaccination and TAI of ≤0. 
Overall response to vaccination—defined as the percent 
of all individual cows that had any detectable increase 
in antibody titer from vaccination to TAI—was 39% 
for BVDV 1, 45% for BVDV 2, and 61% for BoHV-
1 (Table 4). When responses were compared between 
group A and group B cows, no significant differences 
were noted for BVDV 1 and BVDV 2 response to vac-
cination; however, there was a significantly increased 
percentage of group B cows that responded to vacci-
Figure 2. Serum progesterone concentrations (mean ± SEM). 
Samples for progesterone analysis were obtained at the first and sec-
ond prostaglandin (PGF2α) administration and at timed AI (TAI). n = 
no. of cows in each group available for testing at each sampling point. 
No significant differences in progesterone concentrations were detected 
between groups at any time point. Express FP10 and Triangle 10 from 
Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri.
Table 3. Geometric mean serum neutralizing antibody titers against bovine viral diarrhea virus (BVDV; NADL strain) 1, BVDV 2 (strain 
125C), and bovine herpesvirus-1 (BoHV-1; Colorado strain)
Group1
BVDV type 1a (NADL)
 
BVDV type 2 (125C)
 
BoHV-1 (Colorado)
At vaccination At TAI2 At vaccination At TAI At vaccination At TAI
Group A 371.8 451.1  138.7 202.7  10.4 13.5
Group B 343.2 416.4  143.4 197.4  9.8 24.3
P-value 0.61 0.57  0.86 0.86  0.67 <0.0001
1Group A cows received a multivalent modified-live viral vaccine (Express FP 10, Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO), 
whereas group B cows received a multivalent killed viral vaccine (Triangle 10, Boehringer Ingelheim Vetmedica Inc.).
2TAI = timed AI.
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nation based upon BoHV-1 antibody titers compared 
with group A cows (Table 3). In primiparous cows that 
were seronegative to BoHV-1 at vaccination (group A: 
n = 5; group B: n = 6), all had a positive response to 
vaccination. For the single group B cow that was sero-
negative to BVDV 1 and BVDV 2 at vaccination, the 
titers to each virus had increased at TAI. For the cows 
that had BVDV 2 titers <16 at vaccination (group A: 
n = 4; group B: n = 6), all cows had 2-fold or greater 
increases in BVDV 2 antibody titer with the exception 
of 1 group B cow, in which a single-fold increase in 
titer was observed. Pregnancy rates were also evaluated 
in primiparous cows that were randomly selected for 
antibody determination, and a comparison was made 
between cows that had a positive response versus cows 
that had no response to vaccination. No significant 
differences were observed when comparing pregnancy 
rates within group A and group B between primiparous 
cows that had a positive response to vaccination and 
primiparous cows that had no response to vaccination 
(data not shown).
DISCUSSION
The primary objective of this research was to evaluate 
reproductive safety associated with administration of 
MLV vaccines containing BVDV and BoHV-1 fractions 
on subsequent fertility of dairy cattle when vaccination 
and initiation of an estrus synchronization program oc-
cur close in time within the first 60 d postpartum. Ad-
ministration of an MLV vaccine containing BVDV or 
BoHV-1 at less than 28 d before breeding is considered 
Figure 3. Number of cows categorized by magnitude of response to vaccination according to group allocation and bovine viral diarrhea virus 
(BVDV) 1, BVDV 2, or bovine herpesvirus-1 (BoHV-1) antibodies. Individual cow responses to vaccination were calculated based upon the log2 
titer difference between samples taken at vaccination and at timed AI (TAI). A response to vaccination was defined as a 1-fold to 5-fold increase 
in log2 titer. No response to vaccination was defined as a stable (0) or 1-fold to 4-fold decrease in log2 titer. Express FP10 and Triangle 10 from 
Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri.
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an off-label use, irrespective of immune status; however, 
similar cautions do not exist for using MLV vaccines 
within 28 d of initiating an estrus synchronization-TAI 
program. Data on reproductive safety of MLV vaccines 
administered to reproductive age cattle are conflicting, 
with adverse (Perry et al., 2013) or no effects observed 
(Bolton et al., 2007; Walz et al., 2015). Perry et al. 
(2013) compared MLV and KV vaccine administration 
on reproductive hormone concentrations and pregnancy 
rates when initial vaccination was performed in naïve 
crossbred beef heifers at the time of estrus synchroniza-
tion and 8 d before timed AI (Perry et al., 2013). Preg-
nancy rates were reportedly greater in unvaccinated 
heifers and heifers vaccinated or revaccinated with KV 
vaccines compared with heifers receiving their initial 
MLV vaccine (Perry et al., 2013). Furthermore, heifers 
given the MLV vaccine had a greater percentage of ab-
normal estrous cycles compared with the unvaccinated 
and KV vaccinated groups. Use of naïve heifers and 
administration of MLV vaccine to naïve cattle within 
28 d of breeding had a major effect on the findings of 
that study. Other studies have evaluated the effect of 
vaccination on fertility where heifers possessed immu-
nity to BoHV-1 and BVDV acquired through previous 
vaccination (Bolton et al., 2007; Walz et al., 2015). No 
difference in pregnancy rates was observed when MLV 
vaccines were administered at 40 d or 3 d before breed-
ing of heifers that had been vaccinated previously with 
the same product (Kleinhenz et al., 2014). In a recent 
study involving beef heifers, vaccination with MLV vac-
cine did not result in a significant negative reproduc-
tive effect based upon duration of interestrus intervals, 
proportion of heifers exhibiting estrus within 5 d after 
synchronization, serum progesterone concentrations, 
pregnancy rates, or pregnancies in the first 5 d of the 
breeding season when revaccination was performed at 
10 or 31 d before synchronized natural breeding (Walz 
et al., 2015). Immunity acquired through previous vac-
cination is a key feature of studies demonstrating no 
adverse effect of MLV vaccination on fertility and is 
important when evaluating the data from the current 
study. In our study, primiparous dairy cows had re-
ceived 3 doses of MLV vaccine before first breeding and 
an additional dose during first gestation and, although 
this strategy may be used by dairy operations, beef 
operators usually do not vaccinate their calves and 
cows with such frequency. Different levels of immunity 
acquired through previous vaccination might also affect 
fertility following administration of MLV vaccines close 
to time of breeding.
The double-Ovsynch protocol was used on the pri-
miparous dairy cows in this study; this protocol uses 
an Ovsynch protocol [GnRH-(7 d later)-PGF2α-(3 d 
later)-GnRH] followed by a second Ovsynch protocol. 
The protocol relies on the first Ovsynch (pre-Ovsynch) 
to induce cyclicity in anovular cows to cycle and to 
presynchronize cycling cows before entering the second 
Ovsynch (breeding-Ovsynch). Use of MLV vaccines 
within 28 d of the initiation of the double-Ovsynch pro-
tocol might cause transient subfertility that could affect 
response to synchronization and result in a decreased 
pregnancy rate at TAI; however, when compared with a 
peer group of primiparous dairy cows receiving the KV 
vaccine (group B), the group of dairy cows receiving 
the MLV vaccine (group A) displayed no significant 
differences in pregnancy rate and serum P4 concentra-
tions during the double-Ovsynch protocol.
The overall pregnancy rate of 43% reported in this 
study was lower than traditional observations on the 
farm (46% for this farm in 2012; unpublished data) and 
is lower than 52.5% pregnancy per AI rate observed in 
previous studies utilizing the double-Ovsynch protocol 
in primiparous dairy cows (Herlihy et al., 2012; Carv-
alho et al., 2014). In contrast to Herlihy et al. (2012), 
where DIM at TAI was 81 ± 3 d, the DIM at TAI in the 
present study was 68 d. This earlier TAI date along with 
a less than optimal body condition and fewer days at 
the home farm before calving of the primiparous cows 
used in the present study (T. Montgomery, personal ob-
servation) could have resulted in a lower than expected 
Table 4. Proportion (%) of cows defined as responding or not responding to vaccination based upon differences in the log2 antibody titers 
between vaccination and timed AI1
Response2
BVDV type 1a (NADL)
 
BVDV type 2 (125C)
 
BoHV-1 (Colorado)
Group A Group B Group A Group B Group A Group B 
Response to vaccination 40 38   45 45   42 79
No response to vaccination 60 63   55 55   58 21
P-value 0.78 1.0 <0.0001
1Group A cows received a multivalent modified-live viral vaccine (Express FP 10, Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO), 
whereas group B cows received a multivalent killed viral vaccine (Triangle 10, Boehringer Ingelheim Vetmedica Inc.). BVDV = bovine viral 
diarrhea virus; BoHV = bovine herpes virus.
2A response to vaccination was defined as a difference between the log2 titer at vaccination and timed AI ≥1. No response to vaccination was 
defined as a difference between the log2 titer at vaccination and timed AI of ≤0.
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pregnancy rate. The effect of energy status during the 
transition period—from 3 wk before to 3 wk after calv-
ing—on reproductive efficiency in dairy cattle has been 
demonstrated in multiple studies (Ospina et al., 2010; 
Garverick et al., 2013; Carvalho et al., 2014). Body 
condition at TAI and loss of body condition between 
parturition and 21 d postpartum have a major effect on 
pregnancy per AI. Pregnancy per AI for primiparous 
cows that lost condition from parturition to 21 DIM 
at the 40-d pregnancy check was only 30.8% compared 
with 46.9 and 85.8% for primiparous cows that main-
tained or gained condition, respectively (Carvalho et 
al., 2014). An attempt was made to limit the influence 
of poor body condition on fertility in the present study 
by excluding all heifers with a BCS of 1; however, de-
termining loss of body condition between parturition 
and vaccination and determining body condition at 
TAI could have provided more useful information on 
the influence of body condition on pregnancy rate, and 
potentially on antibody responses to vaccination.
When designing this experiment, we decided to use 
KV vaccine as the control group treatment rather than 
including a group of primiparous cows that remained 
unvaccinated. Although including an unvaccinated con-
trol group in the study design would have been optimal 
to evaluate the effect of vaccination in general on dairy 
cow fertility, the risk of reproductive problems associat-
ed with infection with field strains of BVDV or BoHV-1 
was considered too high to leave a population of cows 
unvaccinated. Exposure to field strains of BVDV or 
BoHV-1 before enrollment in or during the study cannot 
be definitively excluded. At the time of vaccination, the 
majority of study animals had serum viral neutralizing 
antibody titers to BVDV and BoHV-1, likely the result 
of vaccination as young calves and vaccination within 
60 d before calving. Although exposure to field strains 
of BVDV and BoHV-1 could have occurred before the 
study, presence of serum neutralizing antibody titers 
<1,024 in >90% of the study cattle makes exposure to 
field strains less likely.
Although the primary purpose of this study was to 
evaluate safety; that is, the effect of MLV vaccination 
on subsequent fertility, a secondary objective was to 
evaluate serological responses in dairy cattle when 
MLV vaccines were administered during the first month 
following calving. Antibody responses are often referred 
to as a surrogate or secondary assessment for vaccine 
efficacy in the face of a live viral challenge; however, 
serologic responses can be a useful proxy for vaccine 
response and to determine whether an animal is prop-
erly immunized (Dubovi, 2013). Following vaccination, 
MLV- and KV-vaccinated groups of cows exhibited an 
elevation in the geometric mean antibody titers, similar 
to a previous report when multiparous and primiparous 
dairy cattle were administered MLV or KV vaccines at 
35 DIM (Dubovi et al., 2000). In contrast to the previ-
ous report where MLV-vaccinated cattle developed a 
significantly greater antibody titer against BVDV and 
BoHV-1 compared with KV-vaccinated cattle (Dubovi 
et al., 2000), we observed no significant differences 
between MLV- and KV-vaccinated cattle in antibody 
titers to BVDV at TAI (45 d following vaccination) 
but did observe a significantly higher BoHV-1 antibody 
titer in the KV-vaccinated cattle. The significant eleva-
tion in BoHV-1 antibody titers but not BVDV anti-
body titers following KV vaccination is an interesting 
observation in the present study and warrants further 
investigation. In beef calves, a significant increase in 
antibody titer to BVDV 1, BVDV 2, and BoHV-1 was 
observed when a commercially available KV vaccine 
was used to booster 11-mo-old calves that had been 
previously administered 2 doses of a commercially 
available MLV at 1 to 2 mo and again at 5.5 mo of age 
(Royan, 2009). In another study, beef calves adminis-
tered different priming and boosting strategies using 
MLV and KV vaccines demonstrated similar antibody 
responses in calves administered MLV-MLV and MLV-
KV prime-boost strategies (Grooms and Coe, 2002). In 
these studies, elevations in antibody responses to both 
BVDV and BoHV-1 were observed; in contrast, we 
observed elevations only to BoHV-1 and not BVDV in 
the present study. Differences in BVDV vaccine strains 
in the MLV priming and KV boosting vaccines in the 
present study and differences in immune responsiveness 
to BVDV and BoHV-1 in the early lactation period 
might explain this difference in antibody responses.
Although antibody titers cannot be compared across 
studies because of differences in animal populations be-
ing tested, cell lines and test strains used in the assay, 
and so on, the magnitude of the response in the present 
study was lower than in a previous report evaluating 
vaccine responses in lactating dairy cattle (Dubovi et 
al., 2000). Primiparous cattle in the present study had 
received 4 doses of MLV vaccine before first parturi-
tion. As a result, the antibody titer at vaccination was 
much higher in our study compared with that in the 
previous report (Dubovi et al., 2000), and this higher 
level of humoral immunity could limit replication of the 
MLV vaccine. The timing of vaccination was different 
as well. In the present study, all cattle were vaccinated 
between 21 and 28 DIM compared with the previous 
study, in which cattle were vaccinated at 35 DIM. As 
the transition period is thought to end around 3 wk 
postpartum (Grummer, 1995), the timing of vaccina-
tion at 21 to 28 DIM is close to the end of the transition 
period. Although data support the high frequency of 
negative energy balance in dairy cattle and the subse-
quent effect on negative health events (mastitis, metri-
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tis), poor reproduction, and lower milk yield, no data 
are available on the effects of negative energy balance 
on vaccine responses when vaccination is performed in 
early lactation. The duration of time between vaccina-
tion and assessing the response to vaccination by mea-
suring antibody titer also differed between our study 
and the previous study (Dubovi et al., 2000). In our 
study, 45 d elapsed between vaccination and assessing 
response to vaccination at TAI as opposed to 14 and 35 
d in the previous report (Dubovi et al., 2000). As such, 
an increase and subsequent decline in the anamnestic 
antibody response over the course of 45 d might also 
affect the observed <60% response to BVDV titers. In 
most studies, response to vaccination as determined 
by antibody titers is usually assessed between 21 and 
28 d following vaccination. In the previous report, the 
antibody titers to BVDV did decline from 14 d after 
vaccination to 35 d after vaccination, albeit slightly 
(Dubovi et al., 2000).
Although the geometric mean antibody titers in-
creased in MLV- and KV-vaccinated cattle in this 
study, the overall percentage of cows that developed 
a humoral immune response was low. Less than 50% 
of cattle in either group had an elevation in antibody 
titer when samples were obtained 45 d after vaccination 
at TAI, with the exception of KV-vaccinated animals 
against BoHV-1. Increases in antibody titers are often 
observed in naïve animals receiving a primary immuni-
zation. The cattle utilized in the present study were not 
naïve, having received 4 doses of MLV vaccine before 
vaccination at 21 to 28 DIM. Poor humoral immune 
responses in a high percent of individual cows following 
vaccination at 21 to 28 DIM raise questions concerning 
vaccination at this time and certainly merits further 
investigation. As stated previously, antibody titers are 
a proxy measurement for vaccine efficacy, where vac-
cination followed by challenge is considered a more ap-
propriate assessment of vaccine efficacy (van Oirschot 
et al., 1999). Evaluation of vaccine efficacy by chal-
lenge experiments in dairy cattle vaccinated under this 
strategy is warranted. Delaying vaccination to 35 DIM 
or for several additional weeks could improve immune 
responsiveness; however, dairy producers are concerned 
about the effects of vaccination at this time on milk 
production and the effects of MLV vaccination on fertil-
ity when administered close to breeding. Milk produc-
tion was not affected by MLV or KV vaccination at 35 
DIM (Dubovi et al., 2000) or when MLV vaccine was 
administered between 21 and 31 DIM to primiparous 
dairy cows (Kleinhenz et al., 2014). Due to concerns 
associated with MLV safety, administration of an MLV 
vaccine containing BVDV or BoHV-1 at less than 28 d 
before breeding is considered an off-label use, irrespec-
tive of immune status. Delaying vaccination beyond 
28 DIM could push the administration to within the 
pre-Ovsynch portion of the synchronization or between 
the pre-Ovsynch and breeding-Ovsynch portions of the 
double-Ovsynch program. Use of MLV or KV vaccines 
before initiation of an estrus synchronization-TAI pro-
gram in dairy cattle should continue to be evaluated, 
especially compared with this use in dairy cows not 
receiving vaccine at this time to thoroughly evaluate 
the effect of vaccination on fertility and milk produc-
tion responses.
CONCLUSIONS
Balancing safety and efficacy of vaccinating cattle 
against viral reproductive pathogens is critically impor-
tant to the profitability of dairy farms. In this research, 
use of MLV vaccine, compared with KV vaccine, did 
not impede reproduction when revaccination was per-
formed between 21 and 28 DIM and 17 d before enroll-
ment in an estrus synchronization-TAI program in pri-
miparous dairy cows; however, response to vaccination 
as defined by increases in virus-specific antibody titers 
should be considered less than ideal for this population 
of cattle. The proportion of cows that had an increase 
in BVDV-specific antibody titers was less than 50% for 
both groups. This finding could indicate that use of 
vaccines directed against viral reproductive pathogens 
may not be as efficacious in this population due to the 
high energy demands and stress associated with the 
postpartum period in primiparous dairy cows.
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